 |
|
A Prospective Trial of Infliximab Therapy for Refractory Uveitis
Preliminary Safety and Efficacy Outcomes
Eric B. Suhler, MD;
Justine R. Smith, MBBS, PhD;
Michael S. Wertheim, MBChB, MRCOphth;
Andreas K. Lauer, MD;
Daryl E. Kurz, MD;
Terri D. Pickard, COT;
James T. Rosenbaum, MD
Arch Ophthalmol. 2005;123:903-912.
Objective Infliximab, a monoclonal antibody against tumor necrosis factor  , is approved by the US Food and Drug Administration for treatment of numerous autoimmune disorders. We conducted a prospective, open-label phase 2 clinical trial to assess the effectiveness of infliximab in treating refractory autoimmune uveitis.
Methods We prospectively enrolled 23 patients from the uveitis clinic of the Casey Eye Institute, Portland, Ore, into this trial. All patients meeting eligibility criteria received 3 infliximab infusions at weeks 0, 2, and 6. Clinical success was ascertained at week 10. Patients meeting initial criteria for success received an infusion at week 14 and every 8 weeks thereafter, with dose escalation permitted for breakthrough inflammation, and underwent outcome measurements at week 50.
Results All patients underwent outcome assessment at week 10. Eighteen (78%) of these subjects met criteria for clinical success at this time. Success was judged by the composite clinical end point of visual acuity, control of intraocular inflammation, ability to taper concomitant medication therapy, and improvement in inflammatory signs on fluorescein angiography and/or ocular coherence tomography. Successful grading required improvement in at least 1 of 4 subcomponents and worsening in none. Seven of 14 patients enrolled for 1 year continued infliximab therapy and maintained their successful grading. Five did not complete 1 year of treatment because of significant adverse events, and 2 terminated treatment early for reasons unrelated to the study. Serious adverse events that were potentially related to infliximab included pulmonary embolus, congestive heart failure, lupus-like reaction in 2, and vitreous hemorrhage in 2 patients. Antinuclear antibodies developed in 15 of 20 enrolled patients receiving 3 or more infusions.
Conclusions Infliximab was an effective short-term immunosuppressive agent in most of the patients, with 18 of 23 meeting criteria for clinical success at week 10. Infliximab was effective in the long term in all patients able to complete 50 weeks of therapy. Although some patients achieved clear benefit, the rate of serious toxic effects was unexpectedly high. Further long-term studies are warranted to determine the safety and efficacy of infliximab in treating intraocular inflammation.
Author Affiliations: Uveitis (Drs Suhler, Smith, Wertheim, Kurz, and Rosenbaum and Ms Pickard) and Retina (Dr Lauer) Divisions, Casey Eye Institute, and Departments of Medicine and Cell Biology (Dr Rosenbaum), Oregon Health and Science University, and Department of Ophthalmology, Portland Veterans Affairs Medical Center (Dr Suhler), Portland, Ore. Dr Wertheim is now in academic practice training in Bristol, England; Dr Kurz is in private practice in Columbus, Ohio.
RELATED LETTERS
Infliximab in Uveitis Treatment
Nathan Rudometkin, Naresh Mandava, Kevin Deane, and Jeffrey L. Olson
Arch Ophthalmol. 2006;124(8):1211.
EXTRACT
| FULL TEXT
Infliximab in Uveitis Treatment—Reply
Eric B. Suhler, Justine R. Smith, Michael S. Wertheim, Andreas K. Lauer, Daryl E. Kurz, Terri D. Pickard, and James T. Rosenbaum
Arch Ophthalmol. 2006;124(8):1211-1212.
EXTRACT
| FULL TEXT
Optimizing the Use of Tumor Necrosis Factor Inhibitors in Refractory Uveitis
Rani T. Sebastian, Simon P. Harding, Roger C. Bucknall, and Ian A. Pearce
Arch Ophthalmol. 2006;124(10):1505.
EXTRACT
| FULL TEXT
Optimizing the Use of Tumor Necrosis Factor Inhibitors in Refractory Uveitis—Reply
Eric B. Suhler, Justine R. Smith, Michael S. Wertheim, Andreas K. Lauer, Daryl E. Kurz, Terri D. Pickard, and James T. Rosenbaum
Arch Ophthalmol. 2006;124(10):1505-1506.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Treating Intraocular Inflammatory Disease in the 21st Century
Robert Nussenblatt
Arch Ophthalmol. 2005;123(7):1000-1001.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis
Simonini et al.
Rheumatology (Oxford) 2008;0:ken298v1-ken298.
ABSTRACT
| FULL TEXT
Behcet's disease: global epidemiology of an Old Silk Road disease
Keino and Okada
Br. J. Ophthalmol. 2007;91:1573-1574.
FULL TEXT
Anti-TNF-{alpha} Therapy in Seven Patients with Behcet's Uveitis: Advantages and Controversial Aspects
TOGNON et al.
Ann. N. Y. Acad. Sci. 2007;1110:474-484.
ABSTRACT
| FULL TEXT
Intravitreal Infliximab and Choroidal Neovascularization in an Animal Model
Olson et al.
Arch Ophthalmol 2007;125:1221-1224.
ABSTRACT
| FULL TEXT
Infliximab Therapy for the Treatment of Refractory Ocular Inflammatory Disease
Sobrin et al.
Arch Ophthalmol 2007;125:895-900.
ABSTRACT
| FULL TEXT
Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease
Sharma et al.
Ann Rheum Dis 2007;66:840-841.
FULL TEXT
Osteopontin Aggravates Experimental Autoimmune Uveoretinitis in Mice
Kitamura et al.
J. Immunol. 2007;178:6567-6572.
ABSTRACT
| FULL TEXT
Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations
Sfikakis et al.
Rheumatology (Oxford) 2007;46:736-741.
FULL TEXT
Adalimumab in the therapy of uveitis in childhood
Mansour
Br. J. Ophthalmol. 2007;91:274-276.
FULL TEXT
Adalimumab in the therapy of uveitis in childhood
Biester et al.
Br. J. Ophthalmol. 2007;91:319-324.
ABSTRACT
| FULL TEXT
Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients
Bodaghi et al.
Br. J. Ophthalmol. 2007;91:335-339.
ABSTRACT
| FULL TEXT
Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome
Teoh et al.
Br. J. Ophthalmol. 2007;91:263-264.
FULL TEXT
Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease
Baker et al.
Br. J. Ophthalmol. 2006;90:1481-1485.
ABSTRACT
| FULL TEXT
Optimizing the Use of Tumor Necrosis Factor {alpha} Inhibitors in Refractory Uveitis
Sebastian et al.
Arch Ophthalmol 2006;124:1505-1505.
FULL TEXT
Optimizing the Use of Tumor Necrosis Factor {alpha} Inhibitors in Refractory Uveitis--Reply
Suhler et al.
Arch Ophthalmol 2006;124:1505-1506.
FULL TEXT
Infliximab in Uveitis Treatment.
Rudometkin et al.
Arch Ophthalmol 2006;124:1211-1211.
FULL TEXT
Infliximab in Uveitis Treatment--Reply
Suhler et al.
Arch Ophthalmol 2006;124:1211-1212.
FULL TEXT
Tumour necrosis factor {alpha} inhibitors in the treatment of childhood uveitis
Saurenmann et al.
Rheumatology (Oxford) 2006;45:982-989.
ABSTRACT
| FULL TEXT
Treating Intraocular Inflammatory Disease in the 21st Century
Nussenblatt
Arch Ophthalmol 2005;123:1000-1001.
FULL TEXT
|
